Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.31 |
| ▸ | HTR1D | P28221 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821294 | 0.90 | KMT2A (0.33) | HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL25461128 | 0.86 | ADAM17 (0.34) | KDM4EADAM17HTR1D | |
| SCHEMBL25821292 | 0.84 | TLR9 (0.38) | — | |
| SCHEMBL25821293 | 0.84 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL25822499 | 0.80 | ADAM17 (0.31) | ADAM17 | |
| SCHEMBL25820210 | 0.79 | HTR2A (0.49) | HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25820235 | 0.78 | IKBKB (0.32) | — | |
| SCHEMBL25824307 | 0.77 | KDM4E (0.33) | HTR2AHTR2CHTR2BKDM4EHTR1D | |
| SCHEMBL23999682 | 0.76 | EHMT2 (0.32) | KDM4EHTR1D | |
| SCHEMBL24010035 | 0.76 | EHMT2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | HTR2A 2819/4885HTR2C 2539/4885HTR2B 3066/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | HTR2A 2539/4885HTR2C 2111/4885HTR2B 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.